Effects of dietary oils prepared from the internal organs of the Japanese giant scallop (Patinopecten yessoensis) on cholesterol metabolism in obese type‐II diabetic KK‐Ay mice

Sugimoto, Koki; Hosomi, Ryôta; Yoshida, Minoru; Fukunaga, Kohji

doi:10.1002/fsn3.1967

Cited by 3 publications

(4 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2 . Our previous study also showed that SCO intake increased liver Cyp7a1 expression level 11 . Hayashi et al reported that increasing taurinebinding βMCA TβMCA , an antagonist of FXR, in the ileum enhanced liver Cyp7a1 expression by suppressing the FXR/SHP1 pathway 47 .…”

Section: Discussionmentioning

confidence: 76%

See 1 more Smart Citation

Comparison of the Cholesterol-Lowering Effect of Scallop Oil Prepared from the Internal Organs of the Japanese Giant Scallop (Patinopecten yessoensis), Fish Oil, and Krill Oil in Obese Type II Diabetic KK-A y Mice

et al. 2021

Self Cite

View full text Add to dashboard Cite

IntroductionThe increase in the incidence of lifestyle-related diseases, including obesity, dyslipidemia, and cardiovascular diseases CVD , has become a social problem in developed countries. In particular, CVD, which causes arteriosclerosis, is one of the leading causes of morbidity and mortality worldwide 1 . Therefore, the prevention or amelioration of dyslipidemia, such as hypertriglyceridemia and hypercholesterolemia, would reduce the risk of CVD 2 . Dietary n-3 polyunsaturated fatty acids PUFA , including eicosapentaenoic acid EPA and docosahexaenoic acid DHA , reduce the incidence and mortality of CVD through multiple mechanisms such as the reduction of serum triacylglyc-

show abstract

Section: Discussionmentioning

confidence: 76%

“…SCO contains higher EPA than standard TAG-type fish oil and includes phospholipids PL and TAG 8 . Our previous study showed that dietary SCO improved lipid metabolism and especially lowered cholesterol levels the serum and liver in obese type II diabetic KK-A y mice 11 . Until now, this effect of SCO has not been compared with other oils containing n-3 PUFA.…”

mentioning

confidence: 94%

Comparison of the Cholesterol-Lowering Effect of Scallop Oil Prepared from the Internal Organs of the Japanese Giant Scallop (Patinopecten yessoensis), Fish Oil, and Krill Oil in Obese Type II Diabetic KK-A y Mice

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Our previous study demonstrated that SCO intake decreased the serum and liver cholesterol content compared with n-3 PUFAcontaining oils, including tuna oil, menhaden oil, and krill oil (28,29). However, it is unclear whether the FA composition or PL of SCO is responsible for this cholesterol-lowering effect.…”

Section: Discussionmentioning

confidence: 99%

“…In addition, SCO contains approximately 20 wt% of PL and includes higher EPA than standard TG-type fish oil (26). Our previous study showed that SCO intake lowered the serum and liver cholesterol contents in mice (28), and this effect was not observed in krill oil and menhaden oil intake (29). However, it is unclear whether the FA composition or PL of SCO has a cholesterol-lowering effect.…”

Section: Introductionmentioning

confidence: 99%

Dietary Phospholipids Prepared From Scallop Internal Organs Attenuate the Serum and Liver Cholesterol Contents by Enhancing the Expression of Cholesterol Hydroxylase in the Liver of Mice

et al. 2021

Self Cite

View full text Add to dashboard Cite

In this study, we successfully prepared scallop oil (SCO), which contains high levels of phospholipids (PL) and eicosapentaenoic acid (EPA), from the internal organs of the Japanese giant scallop (Patinopecten yessoensis), one of the most important underutilized fishery resources in Japan. The intake of SCO lowers the serum and liver cholesterol contents in mice; however, whether the fatty acids (FA) composition or PL of SCO exhibits any cholesterol-lowering effect remains unknown. To elucidate whether the cholesterol-lowering function is due to FA composition or PL of SCO, and investigate the cholesterol-lowering mechanism by SCO, in the present study, mice were fed SCO's PL fraction (SCO-PL), triglyceride (TG)-type oil with almost the same FA composition as SCO-PL, called SCO's TG fraction (SCO-TG), soybean oil (SOY-TG), and soybean's PL fraction (SOY-PL). Male C57BL/6J mice (5-week-old) were fed high-fat and cholesterol diets containing 3% (w/w) experimental oils (SOY-TG, SOY-PL, SCO-TG, and SCO-PL) for 28 days. The SCO-PL diet significantly decreased the serum and liver cholesterol contents compared with the SOY-TG diet, but the intake of SOY-PL and SCO-TG did not show this effect. This result indicated that the serum and liver cholesterol-lowering effect observed in the SCO intake group was due to the effect of SCO-PL. The cholesterol-lowering effect of SCO-PL was in part related to the promotion of liver cholesterol 7α-hydroxylase (CYP7A1) expression, which is the rate-limiting enzyme for bile acid synthesis. In contrast, the expression levels of the ileum farnesoid X receptor (Fxr) and fibroblast growth factor 15 (Fgf15), which inhibit the expression of liver CYP7A1, were significantly reduced in the SCO-PL group than the SOY-TG group. From these results, the increase in the liver CYP7A1 expression by dietary SCO-PL was in part through the reduction of the ileum Fxr/Fgf15 regulatory pathway. Therefore, this study showed that SCO-PL may be a health-promoting component as it lowers the serum and liver cholesterol contents by increasing the liver CYP7A1 expression, which is not seen in SOY-PL and SCO-TG.

show abstract

Influence of Lipid Class Used for Omega-3 Fatty Acid Supplementation on Liver Fat Accumulation in MASLD

Sabinari,

Horakova,

Cajka

et al. 2024

Physiol Res

View full text Add to dashboard Cite

Metabolic dysfunction-associated steatotic liver disease (MASLD) occurs in subjects with obesity and metabolic syndrome. MASLD may progress from simple steatosis (i.e., hepatic steatosis) to steatohepatitis, characterized by inflammatory changes and liver cell damage, substantially increasing mortality. Lifestyle measures associated with weight loss and/or appropriate diet help reduce liver fat accumulation, thereby potentially limiting progression to steatohepatitis. As for diet, both total energy and macronutrient composition significantly influence the liver’s fat content. For example, the type of dietary fatty acids can affect the metabolism of lipids and hence their tissue accumulation, with saturated fatty acids having a greater ability to promote fat storage in the liver than polyunsaturated ones. In particular, polyunsaturated fatty acids of n-3 series (omega-3), such as docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), have been intensively studied for their antisteatotic effects, both in preclinical animal models of obesity and hepatic steatosis and in overweight/obese patients. Their effects may depend not only on the dose and duration of administration of omega-3, or DHA/EPA ratio, but also on the lipid class used for their supplementation. This review summarizes the available evidence from recent comparative studies using omega-3 supplementation via different lipid classes. Albeit the evidence is mainly limited to preclinical studies, it suggests that phospholipids and possibly wax esters could provide greater efficacy against MASLD compared to traditional chemical forms of omega-3 supplementation (i.e., triacylglycerols, ethyl esters). This cannot be attributed solely to improved EPA and/or DHA bioavailability, but other mechanisms may be involved.

show abstract

Effects of dietary oils prepared from the internal organs of the Japanese giant scallop (Patinopecten yessoensis) on cholesterol metabolism in obese type‐II diabetic KK‐A^y mice

Cited by 3 publications

References 49 publications

Comparison of the Cholesterol-Lowering Effect of Scallop Oil Prepared from the Internal Organs of the Japanese Giant Scallop (<i>Patinopecten yessoensis</i>), Fish Oil, and Krill Oil in Obese Type II Diabetic KK-<i>A</i> <sup> <i>y</i> </sup> Mice

Comparison of the Cholesterol-Lowering Effect of Scallop Oil Prepared from the Internal Organs of the Japanese Giant Scallop (<i>Patinopecten yessoensis</i>), Fish Oil, and Krill Oil in Obese Type II Diabetic KK-<i>A</i> <sup> <i>y</i> </sup> Mice

Dietary Phospholipids Prepared From Scallop Internal Organs Attenuate the Serum and Liver Cholesterol Contents by Enhancing the Expression of Cholesterol Hydroxylase in the Liver of Mice

Influence of Lipid Class Used for Omega-3 Fatty Acid Supplementation on Liver Fat Accumulation in MASLD

Contact Info

Product

Resources

About